<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895709</url>
  </required_header>
  <id_info>
    <org_study_id>CA052-002</org_study_id>
    <secondary_id>2021-001188-26</secondary_id>
    <secondary_id>U1111-1265-4508</secondary_id>
    <nct_id>NCT04895709</nct_id>
  </id_info>
  <brief_title>A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of&#xD;
      BMS-986340 as monotherapy and in combination with nivolumab in participants with advanced&#xD;
      solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">August 23, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 27, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to death</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Chemistry panel tests</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters of BMS-986340 administered as monotherapy: Maximum concentration (Cmax)</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of BMS-986340 administered as monotherapy: Time to maximum concentration (Tmax)</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of BMS-986340 administered as monotherapy: Area under the concentration-time curve 1 dosing interval (AUC (TAU))</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of BMS-986340 administered as monotherapy: Observed concentration at the end of the dosing interval (Ctau)</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of BMS-986340 administered in combination with nivolumab: Maximum concentration (Cmax)</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of BMS-986340 administered in combination with nivolumab: Time to maximum concentration (Tmax)</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of BMS-986340 administered in combination with nivolumab: Area under the concentration-time curve in 1 dosing interval (AUC(TAU))</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of BMS-986340 administered in combination with nivolumab: Observed concentration at the end of the dosing interval (Ctau)</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies to BMS- 986340 when administered as monotherapy</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies to BMS- 986340 when administered in combination with nivolumab</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator</measure>
    <time_frame>At 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator</measure>
    <time_frame>At 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator</measure>
    <time_frame>At 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate (PFSR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator</measure>
    <time_frame>At 6 months, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Gastric/Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Microsatellite Stable Colorectal Cancer</condition>
  <condition>Non-Small-Cell Lung Cancer</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Part 1A: BMS-986340 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: BMS-986340 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B: BMS-986340 + Nivolumab Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2B: BMS-986340 + Nivolumab Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986340</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1A: BMS-986340 Dose Escalation</arm_group_label>
    <arm_group_label>Part 1B: BMS-986340 + Nivolumab Dose Escalation</arm_group_label>
    <arm_group_label>Part 2A: BMS-986340 Dose Expansion</arm_group_label>
    <arm_group_label>Part 2B: BMS-986340 + Nivolumab Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-936558-01</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1B: BMS-986340 + Nivolumab Dose Escalation</arm_group_label>
    <arm_group_label>Part 2B: BMS-986340 + Nivolumab Dose Expansion</arm_group_label>
    <other_name>Nivolumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker&#xD;
             analysis&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and&#xD;
             at least 1 lesion accessible for biopsy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1&#xD;
&#xD;
          -  Radiographically documented progressive disease on or after the most recent therapy&#xD;
&#xD;
          -  Received standard-of-care therapies, including an available programmed death&#xD;
             (ligand)-1 inhibitor known to be effective in the tumor type for which they are being&#xD;
             evaluated&#xD;
&#xD;
          -  Parts 1A, 1B, and 2A: Advanced or metastatic non-small cell lung cancer, squamous cell&#xD;
             carcinoma of head and neck, microsatellite stable colorectal cancer, gastric/&#xD;
             gastroesophageal junction adenocarcinoma, or cervical cancer, and have received, be&#xD;
             refractory to, not be a candidate for, or be intolerant of existing therapies known to&#xD;
             provide clinical benefit for the condition of the participant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Primary central nervous system (CNS) malignancy&#xD;
&#xD;
          -  Untreated CNS metastases&#xD;
&#xD;
          -  Leptomeningeal metastases&#xD;
&#xD;
          -  Concurrent malignancy requiring treatment or history of prior malignancy active within&#xD;
             2 years prior to the first dose of study treatment&#xD;
&#xD;
          -  Active, known, or suspected autoimmune disease&#xD;
&#xD;
          -  Condition requiring systemic treatment with either corticosteroids within 14 days or&#xD;
             other immunosuppressive medications within 30 days of the first dose of study&#xD;
             treatment&#xD;
&#xD;
          -  Prior organ or tissue allograft&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  Major surgery within 4 weeks of study drug administration&#xD;
&#xD;
          -  History of or with active interstitial lung disease or pulmonary fibrosis&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gutierrez, Site 0007</last_name>
      <phone>551-996-4725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical Protoco</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Carvajal, Site 0006</last_name>
      <phone>212-342-5162</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center Oncology and Hematology Care- Eastside</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rom Leidner, Site 0001</last_name>
      <phone>503-215-2614</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0009</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0015</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0018</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0020</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Würzburg</city>
        <zip>97078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0019</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0023</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0025</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0013</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0012</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMS-986340</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>CRC</keyword>
  <keyword>First-in-human</keyword>
  <keyword>GEJ</keyword>
  <keyword>Gastric/Gastroesophageal Junction Adenocarcinoma</keyword>
  <keyword>HNSCC</keyword>
  <keyword>Microsatellite Stable Colorectal Cancer</keyword>
  <keyword>MSS CRC</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Non-Small-Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>SCCHN</keyword>
  <keyword>Squamous Cell Carcinoma of Head and Neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

